FDA Needs Bigger Window To The Public, Say Deputies
Executive Summary
FDA may be looking to expand the scope of public discussion in the development of regulatory policy regarding emerging scientific issues
You may also be interested in...
Adaptive Trials Going Mainstream With Industry White Paper, FDA Guidance
Adaptive clinical trials in drug development are moving towards broader acceptance and feasibility with the upcoming publication of an industry white paper and an FDA workshop on the subject
Adaptive Trials Going Mainstream With Industry White Paper, FDA Guidance
Adaptive clinical trials in drug development are moving towards broader acceptance and feasibility with the upcoming publication of an industry white paper and an FDA workshop on the subject
FDA To Provide Updates On Critical Path Opportunities List Projects
FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16